Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
SAB Biotherapeutics, Inc. NASDAQ:SABS | $271.14M | $2.98 | Not rated | 3.0 | -16.45% |
Q32 Bio Inc. NASDAQ:QTTB | $244.96M | $8.23 | Not rated | 5.4 | +302.36% |
AN2 Therapeutics, Inc. NASDAQ:ANTX | $205.65M | $5.71 | Not rated | -4.9 | +358.33% |
Minerva Neurosciences, Inc. NASDAQ:NERV | $152.81M | $3.28 | Not rated | -0.2 | -49.30% |
Verrica Pharmaceuticals Inc. NASDAQ:VRCA | $75.24M | $4.38 | Not rated | -3.5 | -29.91% |
Boundless Bio, Inc. NASDAQ:BOLD | $58.88M | $2.62 | Not rated | -1.0 | +108.70% |
Continue the stock analysis
Jump to another research area for this company.